Recombinant fowl adenovirus bivalent inactivated vaccine

• Main Authors: LU HAO, ZHOU YUSHUANG, WAN ZHIMIN, YE JIANQIANG, WANG WEIKANG, LI TUOFAN, ZHANG JIANJUN, XIE QUAN, LIAN MINGJUN, ZHANG WEI
• Format: Patent
• Language: Chinese; English
• Published: 25.07.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention relates to a recombinant fowl adenovirus bivalent inactivated vaccine. The vaccine is an inactivated recombinant serum 4 type fowl adenovirus FA4-F expressing serum 8b type fowl adenovirus spike protein. The invention relates to a construction method of a recombinant serum 4-type fowl adenovirus FA4-F for expressing serum 8b-type fowl adenovirus spike protein. A serum 8b-type fowl adenovirus spike gene is inserted between F1 and F2 genes of the recombinant serum 4-type fowl adenovirus for expressing EGFP (Enhanced Green Fluorescent Protein). The invention relates to a recombinant fowl adenovirus bivalent inactivated vaccine. According to the inactivation, 0.1% v/v formaldehyde is added into a cell-cultured FA4-F recombinant virus solution to act at 37 DEG C for 24 hours for inactivation; and emulsifying the formaldehyde inactivated virus liquid and an oil adjuvant according to a ratio of 1: 3 (v/v) to prepare the oil adjuvant inactivated vaccine. According to the present invention, the candidate